Saturday, February 25, 2023 12:20:15 PM
That is the main slide I'm interested in as an investor.
That's where income growth can be boosted. If CYRX signs on 11 new approved therapies in 2023, that can only validate the entire growth approach, moving therapies from Ph I to Ph II to Ph III to commercial. Trials are at 654 as of Dec. 2022. From on quarter to the next, that's my first focus.
Best of luck with your investments!
Recent CYRX News
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
